Anbio Biotechnology - Class A Ordinary Shares (NNNN)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Price History
Feb 9, 2026 — Apr 1, 2026Investment Snapshot
- Trading 3,486% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 13.8% — below-average profitability
- Revenue growing at 22% annually
Anbio Biotechnology - Class A Ordinary Shares (NNNN) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $1.1 billion . Key value metrics: P/E ratio 457.9, P/B ratio 63.20, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Anbio Biotechnology - Class A Ordinary Shares — Fundamental Analysis Summary
Anbio Biotechnology - Class A Ordinary Shares (NNNN) is currently trading 3,486% above its Graham Number of $0.72, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 457.9x.
On financial health, NNNN shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 13.8% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.10.
StockPik's composite Value Score for NNNN is 32/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NNNN reports a high gross margin of 71.9% (sector average: 33.5%) and a strong operating margin of 24.4%.
NNNN shows revenue growing at 22% year-over-year, with earnings growing at 5%.